Login / Signup

Molecular and clinical profile of type 2 von Willebrand disease in Iran: a thirteen-year experience.

Maryam RassoulzadeganFereydoun AlaMohammad JazebiMohammad Said EnayatShadi TabibianMahmood ShamsMehran BahrainiAkbar Dorgalaleh
Published in: International journal of hematology (2020)
Type 2 von Willebrand disease (VWD) is the most common congenital bleeding disorder, with variable bleeding tendency and a complex laboratory phenotype. In the current study, we report the clinical and molecular profile of a large number of Iranian patients with type 2 VWD. All exons, intron-exon boundaries, and untranslated regions were sequenced by Sanger sequencing for direct mutation detection. All identified mutations were confirmed in family members and by relevant bioinformatics studies. A total of 136 patients with type 2 VWD were diagnosed, including 42 (30.9%), 32 (23.6%), 38 (27.9%), and 24 (17.6%) patients with type 2A, type 2B, type 2M, and type 2N, respectively. Epistaxis (49%), gum bleeding (30.2%), ecchymosis (23.2%), and menorrhagia (16.3%) were the most common clinical presentations, while miscarriage (2.3%) and umbilical cord bleeding (0.8%) were the rarest. Thirty mutations were identified within the VWF gene, nine (30%) being novel, with p.Arg1379Cys (n = 20), p.Val1316Met (n = 13), p.Arg1597Trp (n = 13), p.Arg1374Cys (n = 10), p.Ser1506Leu (n = 10), and p.Arg1308Cys (n = 9) the most common. Type 2 VWD is a hemorrhagic disorder with variable bleeding tendency and a heterogeneous molecular basis in patients in Iran.
Keyphrases
  • atrial fibrillation
  • mesenchymal stem cells
  • umbilical cord
  • newly diagnosed
  • end stage renal disease
  • bone marrow
  • tyrosine kinase
  • quantum dots
  • peritoneal dialysis
  • copy number
  • patient reported